Literature DB >> 11181932

Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc.

S Kalandakanond1, J A Coffield.   

Abstract

Previously we reported that SNAP-25, synaptobrevin II, and syntaxin I, the intracellular substrates of botulinum toxin originally identified in nontarget tissues, were present in a recognized mammalian target tissue, the mouse hemidiaphragm. Furthermore, we reported that SNAP-25, syntaxin I, and synaptobrevin II were cleaved by incubation of the intact hemidiaphragm in botulinum serotypes A, C, and D, respectively. The objective of the current study was to use the mouse phrenic nerve-hemidiaphragm preparation and botulinum serotype A to investigate 1) the relationship of substrate cleavage to toxin-induced paralysis, and 2) the relevance of substrate cleavage to the mechanism of toxin action. Immunoblot examination of tissues paralyzed by botulinum toxin type A (10(-8) M) revealed < or =10% loss of SNAP-25 immunoreactivity at 1 h postparalysis, and > or =75% loss at 5 h postparalysis. Triticum vulgaris lectin, an agent that competitively antagonizes toxin binding, antagonized toxin-induced paralysis as well as SNAP-25 cleavage. Methylamine hydrochloride, an agent that prevents pH-dependent translocation, also antagonized toxin-induced paralysis and SNAP-25 cleavage. Furthermore, zinc chelation antagonized toxin-induced paralysis and SNAP-25 cleavage. These results demonstrate that cleavage of SNAP-25 by botulinum serotype A fulfills the requirements of the multistep model of botulinum toxin action that includes receptor-mediated endocytosis, pH-dependent translocation, and zinc-dependent proteolysis. Furthermore, the minimal amount of SNAP-25 cleavage at 1 h postparalysis suggests that inactivation of only a small but functionally important pool of SNAP-25 is necessary for paralysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181932

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

1.  Comparison of extracellular and intracellular potency of botulinum neurotoxins.

Authors:  Fang Cai; Carrie B Adrion; James E Keller
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 2.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

Review 3.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

Review 4.  Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.

Authors:  Erkan Kiris; Krishna P Kota; James C Burnett; Veronica Soloveva; Christopher D Kane; Sina Bavari
Journal:  Expert Rev Mol Diagn       Date:  2014-01-23       Impact factor: 5.225

5.  Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery.

Authors:  Erkan Kiris; Jonathan E Nuss; James C Burnett; Krishna P Kota; Dawn C Koh; Laura M Wanner; Edna Torres-Melendez; Rick Gussio; Lino Tessarollo; Sina Bavari
Journal:  Stem Cell Res       Date:  2011-01-19       Impact factor: 2.020

6.  Experience of Botulinum Toxin A Injections for Chronic Migraine Headaches in a Pediatric Chronic Pain Clinic.

Authors:  Lisgelia Santana; Cherry Liu
Journal:  J Pediatr Pharmacol Ther       Date:  2021-02-15

7.  Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.

Authors:  Zdravko Lacković; Boris Filipović; Ivica Matak; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2016-01       Impact factor: 8.739

8.  Botulinum and Tetanus Neurotoxin-Induced Blockade of Synaptic Transmission in Networked Cultures of Human and Rodent Neurons.

Authors:  Phillip H Beske; Aaron B Bradford; Justin O Grynovicki; Elliot J Glotfelty; Katie M Hoffman; Kyle S Hubbard; Kaylie M Tuznik; Patrick M McNutt
Journal:  Toxicol Sci       Date:  2015-11-28       Impact factor: 4.849

9.  Neuritogenic actions of botulinum neurotoxin A on cultured motor neurons.

Authors:  Julie A Coffield; Xiuzhen Yan
Journal:  J Pharmacol Exp Ther       Date:  2009-04-16       Impact factor: 4.030

10.  Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin a.

Authors:  Baskaran Thyagarajan; Natalia Krivitskaya; Joseph G Potian; Kormakur Hognason; Carmen C Garcia; Joseph J McArdle
Journal:  J Pharmacol Exp Ther       Date:  2009-08-04       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.